JP2019534705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534705A5 JP2019534705A5 JP2019520368A JP2019520368A JP2019534705A5 JP 2019534705 A5 JP2019534705 A5 JP 2019534705A5 JP 2019520368 A JP2019520368 A JP 2019520368A JP 2019520368 A JP2019520368 A JP 2019520368A JP 2019534705 A5 JP2019534705 A5 JP 2019534705A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- variable region
- chain variable
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 20
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 16
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 14
- 210000000130 stem cell Anatomy 0.000 claims description 14
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 210000004881 tumor cell Anatomy 0.000 claims description 10
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 208000007452 Plasmacytoma Diseases 0.000 claims description 8
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 8
- 229940127121 immunoconjugate Drugs 0.000 claims description 8
- 206010028537 myelofibrosis Diseases 0.000 claims description 8
- 229940127089 cytotoxic agent Drugs 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 239000002254 cytotoxic agent Substances 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 3
- 229940123237 Taxane Drugs 0.000 claims description 3
- 230000032823 cell division Effects 0.000 claims description 3
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 2
- 101800002638 Alpha-amanitin Proteins 0.000 claims description 2
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims description 2
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims description 2
- 229930188224 Cryptophycin Natural products 0.000 claims description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical class O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 102000003945 NF-kappa B Human genes 0.000 claims description 2
- 108010057466 NF-kappa B Proteins 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- RXGJTYFDKOHJHK-UHFFFAOYSA-N S-deoxo-amaninamide Natural products CCC(C)C1NC(=O)CNC(=O)C2Cc3c(SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)N)C(=O)N4CC(O)CC4C(=O)NC(C(C)C(O)CO)C(=O)N2)[nH]c5ccccc35 RXGJTYFDKOHJHK-UHFFFAOYSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000004007 alpha amanitin Substances 0.000 claims description 2
- CIORWBWIBBPXCG-SXZCQOKQSA-N alpha-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 claims description 2
- CIORWBWIBBPXCG-UHFFFAOYSA-N alpha-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-UHFFFAOYSA-N 0.000 claims description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
- 108010044540 auristatin Proteins 0.000 claims description 2
- 229940044683 chemotherapy drug Drugs 0.000 claims description 2
- 108010006226 cryptophycin Proteins 0.000 claims description 2
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 claims description 2
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229960005501 duocarmycin Drugs 0.000 claims description 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 claims description 2
- 229930184221 duocarmycin Natural products 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 229960005502 α-amanitin Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000000338 in vitro Methods 0.000 claims 2
- 241000750004 Nestor meridionalis Species 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 description 2
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- DLKUYSQUHXBYPB-NSSHGSRYSA-N (2s,4r)-4-[[2-[(1r,3r)-1-acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C DLKUYSQUHXBYPB-NSSHGSRYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101100178170 Caenorhabditis elegans unc-39 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102100040684 Fermitin family homolog 2 Human genes 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101000892677 Homo sapiens Fermitin family homolog 2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
- 229930188854 dolastatin Natural products 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- -1 lenalidomine Chemical compound 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229930184737 tubulysin Natural products 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022026299A JP7235904B2 (ja) | 2016-10-16 | 2022-02-24 | 抗ｉｌ１－ｒａｐ抗体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662408807P | 2016-10-16 | 2016-10-16 | |
| US62/408,807 | 2016-10-16 | ||
| US201662425970P | 2016-11-23 | 2016-11-23 | |
| US62/425,970 | 2016-11-23 | ||
| PCT/US2017/055994 WO2018071455A1 (en) | 2016-10-10 | 2017-10-10 | Isoquinolidinobenzodiazepine (iqb)-1(chloromethyl)-2,3-dihydro-1h-benzo[e]indole (cbi) dimers |
| USPCT/US2017/055994 | 2017-10-10 | ||
| PCT/US2017/056808 WO2018071910A2 (en) | 2016-10-16 | 2017-10-16 | Anti-il1-rap antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022026299A Division JP7235904B2 (ja) | 2016-10-16 | 2022-02-24 | 抗ｉｌ１－ｒａｐ抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534705A JP2019534705A (ja) | 2019-12-05 |
| JP2019534705A5 true JP2019534705A5 (enExample) | 2020-11-26 |
| JP7032394B2 JP7032394B2 (ja) | 2022-03-30 |
Family
ID=67234936
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520368A Active JP7032394B2 (ja) | 2016-10-16 | 2017-10-16 | 抗ｉｌ１－ｒａｐ抗体 |
| JP2022026299A Active JP7235904B2 (ja) | 2016-10-16 | 2022-02-24 | 抗ｉｌ１－ｒａｐ抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022026299A Active JP7235904B2 (ja) | 2016-10-16 | 2022-02-24 | 抗ｉｌ１－ｒａｐ抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11359025B2 (enExample) |
| EP (1) | EP3526247A4 (enExample) |
| JP (2) | JP7032394B2 (enExample) |
| CN (1) | CN110036028B (enExample) |
| AU (1) | AU2017343784A1 (enExample) |
| CA (1) | CA3084459A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| WO2012098407A1 (en) | 2011-01-19 | 2012-07-26 | Cantargia Ab | Anti - il1rap antibodies and their use for treating human |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| WO2020035577A1 (en) | 2018-08-16 | 2020-02-20 | Cantargia Ab | Anti-il1rap antibody compositions |
| EP4013794A4 (en) * | 2019-08-12 | 2023-11-22 | City of Hope | ANTI-IL1RAP ANTIBODIES |
| JP2024500920A (ja) * | 2020-12-23 | 2024-01-10 | カンタージア アクチエボラーグ | 抗ｉｌ１ｒａｐ抗体 |
| CN117062836A (zh) * | 2021-02-05 | 2023-11-14 | 勃林格殷格翰国际有限公司 | 抗il1rap抗体 |
| AU2022215644A1 (en) * | 2021-02-08 | 2023-06-22 | Cdx Medical Ip, Inc. | Dynamically prioritizing, organizing and displaying cells and tissue in order of their diagnostic significance |
| TW202346332A (zh) * | 2021-12-23 | 2023-12-01 | 美商諾瓦瓦克斯股份有限公司 | 抗ＳＡＲＳ－ＣｏＶ－２刺突（Ｓ）抗體及其在治療ＣＯＶＩＤ－１９中的用途 |
| WO2024144806A1 (en) * | 2022-12-29 | 2024-07-04 | Development Center For Biotechnology | Antibodies specific to transmembrane and coiled-coil domain family 3 and uses thereof |
| CN120813608A (zh) * | 2023-02-09 | 2025-10-17 | 希望之城公司 | 抗il1rap抗体及其变体 |
| WO2025024431A1 (en) * | 2023-07-24 | 2025-01-30 | Vanderbilt University | Broadly reactive antibodies to influenza b viruses |
| WO2025126157A1 (en) * | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4811845A (en) | 1987-10-06 | 1989-03-14 | Baggett Jobeth | Medication compliance packaging system and procedure |
| US6417324B1 (en) | 2000-04-21 | 2002-07-09 | Tripep Ab | Synthetic peptides that bind to the hepatitis B virus core and e antigens |
| US20030007976A1 (en) | 1997-12-23 | 2003-01-09 | Watson James D. | Methods and compounds for the treatment of immunologically-mediated skin disorders |
| PT2426144T (pt) | 2007-02-23 | 2019-02-06 | Merck Sharp & Dohme | Anticorpos anti-il-23p19 fabricados por engenharia genética |
| WO2009120903A2 (en) | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| KR20150036824A (ko) * | 2009-03-20 | 2015-04-07 | 제넨테크, 인크. | 이중특이적 항-ｈｅｒ 항체 |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| WO2012098407A1 (en) * | 2011-01-19 | 2012-07-26 | Cantargia Ab | Anti - il1rap antibodies and their use for treating human |
| US9163090B2 (en) * | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
| US20150315279A1 (en) * | 2012-12-21 | 2015-11-05 | Cellerant Therapeutics, Inc. | Antibodies that bind membrane-bound il1rap |
| SG11201601005XA (en) | 2013-08-12 | 2016-03-30 | Genentech Inc | 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| GB201413913D0 (en) | 2014-08-06 | 2014-09-17 | Cantargia Ab | Novel antibodies and uses thereof |
| US9504694B2 (en) | 2015-03-19 | 2016-11-29 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| EP3522932A4 (en) | 2016-10-10 | 2020-06-24 | Cellerant Therapeutics, Inc. | ISOCHINOLIDINOBENZODIAZEPINE (IQB) -1 (CHLORMETHYL) -2,3-DIHYDRO-1-H-BENZO [E] INDOL (CBI) DIMERS |
-
2017
- 2017-10-16 CA CA3084459A patent/CA3084459A1/en not_active Abandoned
- 2017-10-16 US US16/342,176 patent/US11359025B2/en active Active
- 2017-10-16 AU AU2017343784A patent/AU2017343784A1/en not_active Abandoned
- 2017-10-16 JP JP2019520368A patent/JP7032394B2/ja active Active
- 2017-10-16 EP EP17860212.4A patent/EP3526247A4/en active Pending
- 2017-10-16 CN CN201780075197.7A patent/CN110036028B/zh active Active
-
2022
- 2022-02-24 JP JP2022026299A patent/JP7235904B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534705A5 (enExample) | ||
| JP6767362B2 (ja) | リンパ球における阻害経路の中和 | |
| JP2021008487A (ja) | 抗ｎｋｇ２ａ抗体を使用した治療計画 | |
| AU2016233495B2 (en) | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof | |
| KR102022734B1 (ko) | 신규 조절제 및 용법 | |
| RU2020121784A (ru) | Ror1-специфические антигенсвязывающие молекулы | |
| US11384139B2 (en) | Antibody targeting cell surface deposited complement protein C3d and use thereof | |
| WO2010124188A1 (en) | Anti-human ror1 antibodies | |
| WO2014059028A1 (en) | Anti-c16orf54 antibodies and methods of use thereof | |
| JP7755062B2 (ja) | 新規抗ｌ１ｃａｍ抗体 | |
| CN108474793A (zh) | 预后方法 | |
| WO2015161247A1 (en) | Humanized anti-c16orf54 antibodies and methods of use thereof | |
| JP2022509454A (ja) | 癌の処置法 | |
| KR20250039330A (ko) | 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자 | |
| JP2022537703A (ja) | 抗体および使用方法 | |
| TWI822815B (zh) | 抗-人類ｐｄ-ｌ１之抗體及其用途 | |
| JP5884139B2 (ja) | Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬 | |
| US20220372125A1 (en) | Antigen Specific Binding Domains and Antibody Molecules | |
| HK40112932A (zh) | 抗5t4抗体及其用途 | |
| WO2025172587A1 (en) | Binding constructs | |
| WO2025003511A1 (en) | Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules | |
| HK40078173A (en) | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof | |
| RU2020114161A (ru) | Новые анти-cd19-антитела | |
| HK1234068A (en) | Novel modulators and methods of use | |
| HK1234068A1 (en) | Novel modulators and methods of use |